Condition: Dermatitis, Atopic · Sponsor: Janssen Research & Development, LLC
The purpose of this study is to assess how well JNJ-95597528 works compared to placebo in participants with moderate to severe atopic dermatitis (AD).
This description comes directly from the study's public registry record.
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Always discuss trial participation with your own doctor first.
| First OC Dermatology | Fountain Valley, California, United States | Active Not Recruiting |
| University of California Los Angeles - Division of Dermatology | Los Angeles, California, United States | Active Not Recruiting |
| Southern California Dermatology | Santa Ana, California, United States | Active Not Recruiting |
| Driven Research LLC | Miami, Florida, United States | Active Not Recruiting |
| Arlington Dermatology | Rolling Meadows, Illinois, United States | Active Not Recruiting |
| Dawes Fretzin Clinical Research Group | Indianapolis, Indiana, United States | Completed |
| Henry Ford Health System | Detroit, Michigan, United States | Active Not Recruiting |
| Red River Research Partners LLC | Fargo, North Dakota, United States | Active Not Recruiting |
| Oregon Dermatology and Research Center | Portland, Oregon, United States | Active Not Recruiting |
| Clinical Research Philadelphia | Philadelphia, Pennsylvania, United States | Active Not Recruiting |
| Center for Clinical Studies | Houston, Texas, United States | Completed |
| Progressive Clinical Research | San Antonio, Texas, United States | Active Not Recruiting |
+ 50 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07230860